Merck acquires Verona Pharma for $10Bn In The Latest Biotech Buyout
-
最新报道：Merck & Co. has agreed to acquire Verona Pharma for $1 billion, marking another major biotech buyout this year. The deal will give Merck access to Verona's promising respiratory drug ensifentrine, currently in late-stage trials for chronic obstructive pulmonary disease (COPD). Verona shareholders will receive $15 per share in cash, representing a 53% premium over the stock's last closing price. Analysts see this acquisition as Merck's strategic move to strengthen its respiratory portfolio amid growing competition in the COPD treatment market. The transaction is expected to close in Q4 2023, pending regulatory approvals.
下一篇
El Salvador President has a one-word response to Democrats
- El Salvador's President Nayib Bukele responded sharply to U.S. Democratic lawmakers' conce...
24小时热点
热点专题
412668